Moderna, Inc. (MRNA)
|Net Income (ttm)||3.49B|
|Day's Range||333.40 - 341.52|
|52-Week Range||65.49 - 497.49|
|Price Target||340.17 (+0.4%)|
|Est. Earnings Date||Nov 4, 2021|
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu... [Read more...]
In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.Financial Statements
According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 340.17, which is an increase of 0.44% from the latest price.
TThe US health regulators have widened the country's COVID-19 vaccine campaign after the FDA-approved booster shots for Moderna Inc. (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) vaccines. The FDA al...
Corona Doom 2.0: Carter Worth Warns That Vaccine-Maker Moderna May Have Further To Fall. What To Do If You're Long.
Moderna: Look Out Below? COVID-19 vaccine maker Moderna, Inc. (NASDAQ: MRNA) was our top name in late August.
FDA authorizes Moderna, J&J Covid boosters as Pfizer posts new efficacy data
CNBC's Meg Tirrell joins 'Squawk Box' to report on the FDA's latest authorization for Covid-19 booster shots from Moderna and Johnson & Johnson, as well as Pfizer's latest booster efficacy data.
Baillie Gifford Trimmed Positions In Alibaba, Tesla, Nio, Moderna In Q3, Here's What It Bought Instead
Investment firm Baillie Gifford lowered exposure in Tesla Inc (NASDAQ:TSLA), Alibaba Group Holding (NYSE:BABA) and Nio Inc (NYSE:NIO) in the third quarter and snapped up shares in vaccine maker Moderna ...
The U.S. Food and Drug Administration on Wednesday approved booster shots of Moderna Inc.'s (NASDAQ: MRNA) and Jonson & Johnson's (NYSE: JNJ) COVID-19 vaccines as well as authorized “mixing and matching...
The administration also said it'll allow eligible people to "mix and match" different COVID-19 shots when they get their booster.
FDA clears Covid boosters for J&J, Moderna and allows 'mix and match' shots
Meg Tirrell joins 'Closing Bell' to report the FDA has issued Covid boosters for Moderna and J&J. The eligibility groups for Moderna and Pfizer boosters currently remain the same.
FDA Approves Moderna And J&J Covid Booster Shots, Signs Off On Mix-And-Match Approach — Here's Who Is Eligible
All three Covid-19 vaccines now have booster shots authorized — but eligibility for extra doses depends on the specific vaccine.
The company's COVID-19 vaccine might have set the stage for something big.
If you already own MRNA stock, it's too early to sell. If you do not yet own it?
On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, allowing—as the Europeans have recommended—people who have been vaccinated against Covid-...
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna stock gained almost 6% over the last week (five trading days) outperforming the broader S&P 500 which was up about 2% over the same period. The recent gains come amid some upgrades on the stock ...
At least initially. It could be a different story over the longer term.
Is the biotech sell-off a buying opportunity
Jared Holz, Oppenheimer, on whether the dip in biotech is an opportunity for investors. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Jeff Mills.
The FDA is delaying its decision to authorize Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for adolescents to assess the risk of a rare inflammatory heart condition, Wall Street Journal reported citing...
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
Moderna, Inc. (NASDAQ:MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After bottoming in early October, the stock reversed course and moved higher ...
There's a super-bullish estimate for Moderna's 2022 sales.
Bond investors have a lot on their plate with rising oil prices, a hawkish Bank of England, and hedge fund speculators. Can stocks build on last week's positive earnings?
The vaccine maker has a promising pipeline but an expensive valuation.
The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?